Non-Surgical Targeted Treatments for Patients With Tenosynovial Giant Cell Tumors
This article focuses on noninvasive adjuvant treatment modalities including 4 promising systemic drugs that may benefit patients with TGCTs.
This article focuses on noninvasive adjuvant treatment modalities including 4 promising systemic drugs that may benefit patients with TGCTs.
Anaplastic lymphocyte kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) with central nervous system metastasis is challenging to treat. Over the past decade, approval of ALK inhibitors has improved survival and provided patients with overall greater quality of life than that seen with chemotherapy. A practical approach to the treatment of ALK-positive NSCLC is presented in this article.
The development of HER2-targeted therapies such as pertuzumab and trastuzumab have significantly improved the natural history of HER2+ breast cancer.